Montelukast Ratiopharm (Montelukast Sodium)

Montelukast, the active ingredient in Montelukast Ratiopharm, is a leukotriene receptor antagonist presented as an oral tablet for systemic use. It is indicated for the management of asthma, exercise‑induced bronchoconstriction, and allergic rhinitis in adults and children.

GNH USA supplies Montelukast Ratiopharm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation for global distribution. Our supply chain ensures timely delivery and product integrity across multiple regions.

Montelukast acts on the leukotriene pathway to control airway inflammation and bronchoconstriction. - Asthma: improves long‑term control and reduces the frequency of exacerbations. - Exercise‑induced bronchoconstriction: prevents airway narrowing during physical activity. - Allergic rhinitis: alleviates nasal congestion, sneezing and itchy eyes.

Montelukast may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Headache: mild to moderate pain often reported. - Abdominal pain: discomfort or cramps in the stomach area. - Cough: occasional dry cough. - Nausea: feeling of queasiness. - Diarrhea: loose stools. - Fatigue: general tiredness.

Serious or Rare Side Effects: - Allergic reactions: rash, urticaria, or angioedema. - Neuropsychiatric events: mood changes, agitation, or suicidal thoughts. - Hepatic dysfunction: elevated liver enzymes or hepatitis. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.

When prescribing Montelukast, clinicians should consider several safety measures to optimize patient outcomes. - Assess asthma control: ensure baseline therapy is adequate before adding Montelukast. - Monitor neuropsychiatric symptoms: watch for mood changes or suicidal ideation. - Use caution in hepatic impairment: adjust use if liver disease is present. - Avoid in known hypersensitivity: discontinue if allergic reaction occurs. - Not for acute asthma attacks: it does not provide immediate bronchodilation. - Store at room temperature: keep in the original packaging, protect from moisture and heat.

Montelukast can interact with other medicines, influencing its plasma levels or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, ritonavir): may increase Montelukast exposure. - Strong CYP2C9 inhibitors (e.g., fluconazole): can raise drug concentrations. - Concurrent use with potent enzyme inducers such as phenobarbital or rifampin: may reduce efficacy significantly.

Moderate Interactions (Monitor Closely): - Warfarin: potential alteration of anticoagulant effect. - Theophylline: possible additive bronchial effects. - Antidepressants (e.g., SSRIs): monitor for enhanced neuropsychiatric side effects. - St. John’s wort herbal supplement: may lower Montelukast levels.